Skip to main content
BenevolentAI logo

BenevolentAI — Investor Relations & Filings

Ticker · BAI ISIN · LU2355630455 LEI · 2221003P54KEDC3P4Z33 AS Professional, scientific and technical activities
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-04-17 AGM Information
Country LU Luxembourg
Listing AS BAI

About BenevolentAI

https://www.benevolent.com/

BenevolentAI is a clinical-stage company that specializes in applying artificial intelligence (AI) and machine learning to drug discovery and development. The company utilizes its proprietary technology platform, which is built upon a comprehensive knowledge graph, to analyze vast amounts of complex biomedical information. This platform is designed to generate novel biological insights, identify new therapeutic targets, and accelerate the research and development process for new medicines. By integrating advanced AI with scientific expertise, BenevolentAI aims to decipher complex disease biology and improve the efficiency and success rate of bringing new treatments to patients.

Recent filings

Filing Released Lang Actions
BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24
AGM Information Classification · 1% confidence The document explicitly announces the 'Publication of the Revised Agenda for the 2024 AGM' and provides details about the meeting date, time, and location. This content directly relates to the Annual General Meeting (AGM). Although it is an announcement about the meeting materials, the core subject matter is the AGM itself, making 'AGM Information' (AGM-R) the most appropriate classification, as it concerns the materials shared for the meeting, even if it's a revised agenda announcement. Given the short length (2219 chars) and the focus on publishing meeting documents, it could also be considered an RPA, but since the subject is specifically the AGM agenda, AGM-R is more precise.
2024-04-17 English
BAI_PROPOSED CHANGES TO BOARD COMPOSITION _FINAL_15.04.24
Board/Management Information Classification · 1% confidence The document is explicitly titled "PUBLIC DISCLOSURE OF INSIDE INFORMATION IN ACCORDANCE WITH ARTICLE 17(1) OF THE REGULATION (EU) NO 596/2014 ON MARKET ABUSE (MARKET ABUSE REGULATION)" and announces "PROPOSED CHANGES TO BENEVOLENTAI'S BOARD COMPOSITION." It details resignations and proposed appointments of Non-Executive Directors, including resolutions to be put forward at the upcoming Annual General Meeting (AGM). While it mentions the AGM, the core content is about changes in senior management/board composition, which aligns directly with the definition for Board/Management Information (MANG). It is not the AGM presentation itself (AGM-R), nor is it a general earnings release (ER) or a formal proxy statement (PSI).
2024-04-15 English
BEN-8744 Phase 1a results FINAL APPROVED
Legal Proceedings Report Classification · 1% confidence The document is a press release dated March 25, 2024, announcing positive topline safety and pharmacokinetic data from a Phase Ia clinical study of a drug candidate (BEN-8744). It details clinical trial results, scientific rationale, management commentary, and includes boilerplate information about the company and forward-looking statements. Crucially, it contains the header: "Public disclosure of inside information in accordance with article 17(1) of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)". This structure strongly indicates an official announcement of material, non-public information to the market. While it contains financial/clinical results, it is presented as a news release summarizing key findings rather than a comprehensive periodic report (like 10-K or IR). This type of announcement, especially when mandated by MAR (EU regulation), is best classified as a general Regulatory Filing or announcement that doesn't fit the specific report types (like ER, which is usually quarterly results). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a formal, market-sensitive announcement that isn't a specific financial report or presentation.
2024-03-25 English
2221003P54KEDC3P4Z33-2023-12-31-en
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-03-20 English
BenevolentAI Convening Notice 2024
AGM Information Classification · 1% confidence The document is explicitly titled a "CONVENING NOTICE" for the "ANNUAL GENERAL MEETING" (AGM) of shareholders, scheduled for May 2, 2024. It details the agenda, proposed resolutions (including approval of financial statements, remuneration, and director appointments/discharges), and voting procedures. This content directly corresponds to the materials prepared for and presented at an AGM. Therefore, the classification is AGM Information (AGM-R).
2024-03-20 English
BAI - Prelims 2023 FINAL LOCKED
Earnings Release Classification · 1% confidence The document explicitly states it contains "Unaudited preliminary results for the year ended 31 December 2023" and presents detailed financial highlights, including revenue, operating loss, and EPS comparisons between 2023 and 2022. This content structure—preliminary results announced early in the year for the preceding fiscal year—is characteristic of an Earnings Release (ER), which provides the initial announcement of key financial results. While it contains detailed financial figures, it is presented as a press release announcing these results, rather than the comprehensive, audited Annual Report (10-K) or a detailed Management Discussion & Analysis (MDA). The document also includes operational highlights and management commentary, typical of an ER. FY 2023
2024-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.